Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1998 July; 91(7): 360–364.
PMCID: PMC1296808

Targeting of dornase alpha therapy in adult cystic fibrosis.


Although dornase alpha (recombinant human DNase) can thin the viscid pulmonary secretions of cystic fibrosis (CF), clinical trials in groups of unselected patients have shown only modest average improvements in pulmonary function. The product is very expensive, so in conjunction with purchasers we designed selection criteria and a protocol for a 2-week trial to target CF individuals who might gain most benefit. Treatment was to be continued in those showing > or = 10% improvement in pulmonary function. Those who had a trial of dornase alpha were followed up for 2 years. Of 25 patients who had a 2-week trial of dornase alpha, 17 met the criteria for continuation (average gain in forced expiratory volume 37%). The 11 of these who were still alive at 2 years had a greater initial average FEV1 improvement than those who had died (45% versus 22%), and still had an average improvement of 31% at 2 years. The 8 patients who did not meet the criteria for continuation were older and had required fewer intravenous antibiotic courses. All these were alive at 2 years with unchanged clinical indices. This method of selection for dornase alpha treatment allows targeting to those who gain most benefit without disadvantaging the remaining patients. Furthermore, production of such guidelines in conjunction with purchasers obviates funding difficulties and allows rational prescribing.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (747K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax. 1996 Feb;51(2):119–125. [PMC free article] [PubMed]
  • SALOMON A, HERCHFUS JA, SEGAL MS. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann Allergy. 1954 Jan-Feb;12(1):71–77. [PubMed]
  • Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis. 1968 Oct;98(4):697–698. [PubMed]
  • Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed]
  • Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul;148(1):145–151. [PubMed]
  • Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. [PubMed]
  • Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax. 1995 Apr;50(4):333–338. [PMC free article] [PubMed]
  • Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CA, Light MC, Scott SF, Tullis DE, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J. 1995 Jun;8(6):954–958. [PubMed]
  • Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. [PubMed]
  • Nickerson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Robertson G. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis. 1980 Dec;122(6):859–866. [PubMed]
  • Cooper PJ, Robertson CF, Hudson IL, Phelan PD. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 1990;8(1):16–22. [PubMed]
  • Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med. 1995 Aug;89(7):499–502. [PubMed]
  • Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol. 1997 Apr;23(4):243–248. [PubMed]
  • Corey M, Levison H, Crozier D. Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis. 1976 Dec;114(6):1085–1092. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press